ArticleScientific reports2016
Evolutionary prediction of medicinal properties in the genus Euphorbia L.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Euphol targets key oncogenic processes and promotes chemoprevention in organoid and In Vivo models of colorectal cancers.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2026Article
- Integrative chemotaxonomic and micromorphological insights into Peucedanum (Apiaceae).Scientific reports · 2026Article
- AI-Driven Plant-Derived Anti-Infectives: Integrating Traditional Wisdom into Precision Medicine Against AMR.Life (Basel, Switzerland) · 2026Review
- Acteoside exerts neuroprotective effects by preventing α-synuclein aggregation and oxidative stress in models of Parkinson's disease.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Article
- Can Provence Flora Offer Effective Alternatives to Widely Used Medicinal Plants? A Comparative Study of Antioxidant Activity and Chemical Composition Using Molecular Networking.Molecules (Basel, Switzerland) · 2025Article
- Phylogeny, ethnomedicinal use and the distribution of phytoestrogens in the Fabaceae.Frontiers in pharmacology · 2025Article
- An Integrative Study ofPharmaceutics · 2024Article
- Evaluating Potentials of Species Rich Taxonomic Groups in Cosmetics and Dermatology: Clustering and Dispersion of Skin Efficacy of Asteraceae and Ranunculales Plants on the Species Phylogenetic Tree.Current pharmaceutical biotechnology · 2023Article
- A phylogenetic perspective of antiviral species of the genusJournal of herbal medicine · 2022Article
- Antifungal and Cytotoxic Activity of Diterpenes and Bisnorsesquiterpenoides from the Latex ofMolecules (Basel, Switzerland) · 2022Article
- Unprecedented Insights on Chemical and Biological Significance ofPlants (Basel, Switzerland) · 2022Article
- Mass Spectrometry Metabolomics and Feature-Based Molecular Networking Reveals Population-Specific Chemistry in Some Species of theFrontiers in nutrition · 2022Article
- Antitumor Effect of the Ethanolic Extract from Seeds ofNutrients · 2021Article
- Bioactive diterpenoid metabolism and cytotoxic activities of genetically transformed Euphorbia lathyris roots.Phytochemistry · 2020Article
- Evaluation of plant sources for antiinfective lead compound discovery by correlating phylogenetic, spatial, and bioactivity data.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- The Phylum Bryozoa: From Biology to Biomedical Potential.Marine drugs · 2020Review
- Pharmaceutical resource discovery from traditional medicinal plants: Pharmacophylogeny and pharmacophylogenomics.Chinese herbal medicines · 2020Review
- Antimicrobial Activity of Necklace Orchids is Phylogenetically Clustered and can be Predicted With a Biological Response Method.Frontiers in pharmacology · 2020Article
- Ewé: a web-based ethnobotanical database for storing and analysing data.Database : the journal of biological databases and curation · 2020Article
- Assessing the utility of conserving evolutionary history.Biological reviews of the Cambridge Philosophical Society · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current decrease of new drugs brought to the market has fostered renewed interest in plant-based drug discovery. Given the alarming rate of biodiversity loss, systematic methodologies in finding new plant-derived drugs are urgently needed. Medicinal uses of plants were proposed as proxy for bioactivity, and phylogenetic patterns in medicinal plant uses have suggested that phylogeny can be used as predictive tool. However, the common practice of grouping medicinal plant uses into standardised categories may restrict the relevance of phylogenetic predictions. Standardised categories are mostly associated to systems of the human body and only poorly reflect biological responses to the treatment. Here we show that medicinal plant uses interpreted from a perspective of a biological response can reveal different phylogenetic patterns of presumed underlying bioactivity compared to standardised methods of medicinal plant use classification. In the cosmopolitan and pharmaceutically highly relevant genus Euphorbia L., identifying plant uses modulating the inflammatory response highlighted a greater phylogenetic diversity and number of potentially promising species than standardised categories. Our interpretation of medicinal plant uses may therefore allow for a more targeted approach for future phylogeny-guided drug discovery at an early screening stage, which will likely result in higher discovery rates of novel chemistry with functional biological activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.